Litcius/Paper detail

A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant

Naoka Murakami, Patrick M. Mulvaney, Melissa Danesh, Ala Abudayyeh, Adi Diab, Noha Abdel‐Wahab, Maen Abdelrahim, Pascale Khairallah, Shayan Shirazian, Aleksandra Kukla, Itunu Owoyemi, Tarek Alhamad, Samir Husami, Madhav C. Menon, Andrew D. Santeusanio, Christopher D. Blosser, Sandra Carias Zuniga, María José Soler, Francesc Moreso, Zain Mithani, David I. Ortiz-Melo, Edgar A. Jaimes, Victoria Gutgarts, Erik L. Lum, Gabriel M. Danovitch, Francesca Cardarelli, Reed E. Drews, Claude Bassil, Jennifer Swank, Scott G. Westphal, Roslyn B. Mannon, Keisuke Shirai, Abhijat Kitchlu, Song Ong, Shana Machado, Suraj Sarvode Mothi, Patrick A. Ott, Osama E. Rahma, F. Stephen Hodi, Meghan E. Sise, Shruti Gupta, David E. Leaf, Craig Devoe, Rimda Wanchoo, Vinay Nair, Chrysalyne D. Schmults, Glenn J. Hanna, Ben Sprangers, Leonardo V. Riella, Kenar D. Jhaveri

2020Kidney International181 citationsDOIOpen Access PDF

Topics & Concepts

MedicineKidney cancerKidney transplantImmune checkpointCancerOncologyKidney transplantationInternal medicineKidneyImmunotherapyCancer Immunotherapy and BiomarkersRenal Transplantation Outcomes and TreatmentsPolyomavirus and related diseases
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant | Litcius